Handbook of Contemporary Neuropharmacology, 3 Volume Set

Regular price €1,182.90
Title
accessible
advances
agents stemming
approaches
Category=MKG
Category=MKJ
central
current
drug
eq_isMigrated=1
eq_nobargain
general
information
latest
neuropharmacologic
neuropharmacology
novel
potential
prominent experts collaborated
reference
research
role
uptodate

Product details

  • ISBN 9780471660538
  • Weight: 5874g
  • Dimensions: 206 x 269mm
  • Publication Date: 17 Apr 2007
  • Publisher: John Wiley & Sons Inc
  • Publication City/Country: US
  • Product Form: Hardback
Delivery/Collection within 10-20 working days

Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock

10-20 Working Days: On Backorder

Will Deliver When Available: On Pre-Order or Reprinting

We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!

Written and edited by recognized experts, this comprehensive reference is also available online via Wiley InterScience.
  • Provides a readily accessible reference for students, professionals and libraries alike.
  • Editors are recognized authorities in the neuropharmacology and science field.
  • Comprehensive reference text for active junior and senior neurobiologists.
  • Fills an important niche as a text between research publications and clinical applications.

The Handbook of Contemporary Neuropharmacology is an invaluable resource for principal investigators and working scientists in academia, government and industry. This three volume set it also of interest for academic physicians, postdoctoral fellows and residents, and all high-level graduate students.

DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.

ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.